|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||134.16 - 134.99|
|52 Week Range||106.87 - 135.50|
|PE Ratio (TTM)||66.50|
|Expense Ratio (net)||0.06%|
Why is Vanguard voting against a shareholder measure on its proxy ballot that moves to stop investing in companies that "substantially contribute" to genocide?
This has been another year of brisk new product launches from the exchange-traded funds industry as hundreds of new funds have come to market. As is often the case, some new ETFs take awhile to attract ...
According to a Deloitte report, the biosimilars market is expected to grow to a market value of more than $445.0 billion by the end of 2019.
This year, the growth factor resumed its outperformance of the value factor, benefiting a host of exchange traded funds along the way. Investors can easily access growth stocks via ETFs, whether be by ...
ETF adoption has rapidly accelerated in recent years, with many investors steering to cheap ETFs to potentially bolster long-term investment returns. There are 2,040 U.S.-listed ETFs on the market with ...
Goldman Sachs Asset Management is ramping up a price war with the pending launch of a new "smart-beta" exchange-traded fund with an expense ratio as low as 0.09% (or 9 basis points) -- a level even lower than some passive index funds, says Moody's Investors Service. Analyst Stephen Tu writes: GSAM’s move expands the ETF price war beyond plain vanilla ETFs into smart-beta ETFs, implying that the industry’s higher pricing assumptions for smart-beta products will not hold.
Boston Scientific (BSX) expects to register 2017 revenues of $8.9 billion–$9.0 billion compared to its previous guidance of $8.8 billion–$8.9 billion.
In 2Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $324 million, which reflected a whopping ~32% growth on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter ...
An activist group at Vanguard is asking shareholders to vote in favor of a proposal that would not allow the mutual fund giant to invest in companies that contribute to genocide or crimes against humanity. Yahoo Finance’s Alexis Christoforous, Ethan Wolff-Mann and Dan Roberts talk about why Vanguard is recommending its clients to vote against the proposal.